MaaT Pharma SA (MAAT.PA)
- Previous Close
5.46 - Open
5.60 - Bid --
- Ask --
- Day's Range
5.04 - 5.70 - 52 Week Range
5.04 - 9.96 - Volume
25,761 - Avg. Volume
6,129 - Market Cap (intraday)
91.606M - Beta (5Y Monthly) 0.11
- PE Ratio (TTM)
-- - EPS (TTM)
-2.20 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.50
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.
www.maatpharma.comRecent News: MAAT.PA
View More
Performance Overview: MAAT.PA
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAAT.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAAT.PA
View MoreValuation Measures
Market Cap
87.82M
Enterprise Value
83.56M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.18
Price/Book (mrq)
8.50
Enterprise Value/Revenue
25.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.64%
Return on Equity (ttm)
-187.68%
Revenue (ttm)
3.22M
Net Income Avi to Common (ttm)
-28.9M
Diluted EPS (ttm)
-2.20
Balance Sheet and Cash Flow
Total Cash (mrq)
20.15M
Total Debt/Equity (mrq)
154.38%
Levered Free Cash Flow (ttm)
-12.25M